Journal of Cancer Metastasis and Treatment最新文献

Research progress of intestinal microbiota in targeted therapy and immunotherapy of colorectal cancer 肠道微生物群在结直肠癌靶向治疗和免疫治疗中的研究进展

IF 1.9

Journal of Cancer Metastasis and Treatment Pub Date : 2024-03-21 DOI: 10.20517/2394-4722.2023.178

Xinying Zhou, Yu Zhao, Rongchuan Zhao, Shaheryar Shafi, Yue Yang, Guangxing Liu, Song-Bai Liu

引用次数: 0

Editorial on “Chinese expert consensus on the clinical practice of non-small cell lung cancer fusion gene detection based on RNA-based NGS” (2023 edition) 基于RNA的NGS检测非小细胞肺癌融合基因临床实践的中国专家共识》（2023年版）编辑部文章

IF 1.9

Journal of Cancer Metastasis and Treatment Pub Date : 2024-02-20 DOI: 10.20517/2394-4722.2024.02

Qinghua Zhou

引用次数: 0

Leveraging metformin to combat hepatocellular carcinoma: its therapeutic promise against hepatitis viral infections 利用二甲双胍抗击肝细胞癌：其对肝炎病毒感染的治疗前景

IF 1.9

Journal of Cancer Metastasis and Treatment Pub Date : 2024-01-23 DOI: 10.20517/2394-4722.2023.147

Ali Shojaeian, Mohsen Nakhaie, Zahra Sobhi Amjad, Armin Khaghani Boroujeni, Somayeh Shokri, Shahab Mahmoudvand

{"title":"Leveraging metformin to combat hepatocellular carcinoma: its therapeutic promise against hepatitis viral infections","authors":"Ali Shojaeian, Mohsen Nakhaie, Zahra Sobhi Amjad, Armin Khaghani Boroujeni, Somayeh Shokri, Shahab Mahmoudvand","doi":"10.20517/2394-4722.2023.147","DOIUrl":"https://doi.org/10.20517/2394-4722.2023.147","url":null,"abstract":"Hepatocellular carcinoma (HCC) is categorized among the most common primary malignant liver cancer and a primary global cause of death from cancer. HCC tends to affect males 2-4 times more than females in many nations. The main factors that raise the incidence of HCC are chronic liver diseases, hepatotropic viruses like hepatitis B (HBV) and C (HCV), non-alcoholic fatty liver disease, exposure to toxins like aflatoxin, and non-alcoholic steatohepatitis (NASH). Among these, hepatitis B and C are the most prevalent causes of chronic hepatitis globally. Metformin, which is made from a naturally occurring compound called galegine, derived from the plant Galega officinalis (G. officinalis ), has been found to exhibit antitumor effects in a wide range of malignancies, including HCC. In fact, compared to patients on sulphonylureas or insulin, studies have demonstrated that metformin treatment significantly lowers the risk of HCC in patients with chronic liver disease. This article will first describe the molecular mechanism of hepatitis B and C viruses in the development of HCC. Then, we will provide detailed explanations about metformin, followed by a discussion of the association between metformin and hepatocellular carcinoma caused by the viruses mentioned above.","PeriodicalId":15167,"journal":{"name":"Journal of Cancer Metastasis and Treatment","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2024-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139604006","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Mechanical force-mediated interactions between cancer cells and fibroblasts and their role in the progression of hepatocellular carcinoma 机械力介导的癌细胞与成纤维细胞之间的相互作用及其在肝细胞癌进展过程中的作用

IF 1.9

Journal of Cancer Metastasis and Treatment Pub Date : 2024-01-22 DOI: 10.20517/2394-4722.2023.137

Zheng Peng, Yanling Ding, Hongyu Zhang, Xia Meng, Yiyong Huang, Pengfei Zhang, Zepeng Li, Xiaoling Zhou

引用次数: 0

Fast-tracking drug development with biomarkers and companion diagnostics 利用生物标志物和辅助诊断快速开发药物

IF 1.9

Journal of Cancer Metastasis and Treatment Pub Date : 2024-01-18 DOI: 10.20517/2394-4722.2023.134

Noreen McBrearty, Devika Bahal, S. Platero

引用次数: 0

Prognostic value of clonal evolution identified by sequential FISH in untreated chronic lymphocytic leukaemia 在未经治疗的慢性淋巴细胞白血病中，通过连续 FISH 鉴定出的克隆进化具有预后价值

IF 1.9

Journal of Cancer Metastasis and Treatment Pub Date : 2024-01-15 DOI: 10.20517/2394-4722.2023.131

R. Dondolin, Matteo Bellia, S. Rasi, C. Deambrogi, D. Talotta, S. Mouhssine, Wael Al Essa, A. Mahmoud, Danilo Faraci, G. Gaidano, R. Moia

{"title":"Prognostic value of clonal evolution identified by sequential FISH in untreated chronic lymphocytic leukaemia","authors":"R. Dondolin, Matteo Bellia, S. Rasi, C. Deambrogi, D. Talotta, S. Mouhssine, Wael Al Essa, A. Mahmoud, Danilo Faraci, G. Gaidano, R. Moia","doi":"10.20517/2394-4722.2023.131","DOIUrl":"https://doi.org/10.20517/2394-4722.2023.131","url":null,"abstract":"Aim: The aim of the current study was to evaluate the potential clinical impact of clonal evolution detected by fluorescence in situ hybridization (FISH) in untreated chronic lymphocytic leukaemia (CLL) patients managed with a watch-and-wait strategy.\u0000 Methods: We performed both overall survival (OS) and time to first treatment (TTFT) analysis. For the first one, we exploited a real-life cohort of 123 consecutive CLL patients followed at our institution, for which at least a second FISH evaluation during watch and wait was available. For TTFT analysis, we considered only patients treated after the second FISH sample (n = 69).\u0000 Results: Considering the original cohort, patients who acquired a FISH abnormality displayed a worse outcome with a median OS of 91.9 months compared to 147.3 months for patients who did not acquire any FISH abnormalities (P = 0.007). Unmutated immunoglobulin heavy chain gene (IGHV) genes were associated with a higher probability of acquiring a FISH abnormality (P = 0.04). Turning to TTFT analysis, patients who gained at least one FISH abnormality (n = 7, 10%) were characterised by an earlier treatment requirement with a median TTFT of 1.1 months, compared to 2.7 months in patients who did not acquire any FISH abnormalities (n = 62, 90%) (P = 0.025).\u0000 Conclusions: The dynamic acquisition of karyotypic abnormalities by FISH predicts poor outcomes and early treatment requirement in CLL patients. Our results suggest that FISH analysis could be integrated with other clinical and biological features to obtain dynamic scores that are able to predict outcomes at different phases of disease history.","PeriodicalId":15167,"journal":{"name":"Journal of Cancer Metastasis and Treatment","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2024-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139530186","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Drawbacks and Unexpected Advantages of the Response to Modeling Posttraumatic Stress Disorder in Old Wistar Rats 模拟老 Wistar 大鼠创伤后应激障碍的缺点和意想不到的优点

Journal of Cancer Metastasis and Treatment Pub Date : 2023-12-12 DOI: 10.1134/s0012496623700576

M. V. Kondashevskaya, K. A. Artem’eva, M. A. Kozlova, D. A. Areshidze, L. V. Kaktursky

引用次数: 0

Thermal ablation of metastatic disease to the musculoskeletal system 热消融转移到肌肉骨骼系统的疾病

Journal of Cancer Metastasis and Treatment Pub Date : 2023-10-25 DOI: 10.20517/2394-4722.2023.26

Erwin Xia, Ambrose J. Huang

{"title":"Thermal ablation of metastatic disease to the musculoskeletal system","authors":"Erwin Xia, Ambrose J. Huang","doi":"10.20517/2394-4722.2023.26","DOIUrl":"https://doi.org/10.20517/2394-4722.2023.26","url":null,"abstract":"A variety of indications have been published regarding the use of percutaneous thermal ablation for treating tumors of the musculoskeletal system, including bone and soft tissue lesions, benign and malignant lesions, and primary and metastatic tumors. In the appropriately selected patient, the advantages of percutaneous thermal ablation include decreased morbidity, decreased cost, and shorter hospitalization stays compared to surgery. The number of different thermal ablation modalities is increasing, and each modality has its advantages and disadvantages. Studies directly comparing the effectiveness of the various thermal ablation modalities are sparse, however, so the choice of ablation modality often depends on availability, user preference, and local expertise. Although the list of uses for percutaneous thermal ablation is ever-expanding, in this article, we will discuss the two most well-established indications, which are palliation of pain attributed to bone and soft tissue metastases and local control of oligometastatic disease. Numerous clinical trials have shown percutaneous thermal ablation to be an effective method of palliating pain due to bone and soft tissue metastases and of achieving local control in the setting of oligometastatic disease with low rates of complication.","PeriodicalId":15167,"journal":{"name":"Journal of Cancer Metastasis and Treatment","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134971975","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Does delaying surgery following induction chemotherapy compromise survival in patients with mesothelioma? 诱导化疗后延迟手术是否会影响间皮瘤患者的生存?

Journal of Cancer Metastasis and Treatment Pub Date : 2023-09-15 DOI: 10.20517/2394-4722.2023.57

Lye-Yeng Wong, Ioana Baiu, Matthew Leipzig, Ashley Titan, Douglas Z. Liou, Natalie Lui, Mark Berry, Joseph B. Shrager, Leah Backhus

{"title":"Does delaying surgery following induction chemotherapy compromise survival in patients with mesothelioma?","authors":"Lye-Yeng Wong, Ioana Baiu, Matthew Leipzig, Ashley Titan, Douglas Z. Liou, Natalie Lui, Mark Berry, Joseph B. Shrager, Leah Backhus","doi":"10.20517/2394-4722.2023.57","DOIUrl":"https://doi.org/10.20517/2394-4722.2023.57","url":null,"abstract":"Objective: The ideal time interval between induction chemotherapy and surgery and the impact on cancer mortality in patients with mesothelioma remains unclear. Methods: We queried the National Cancer Database (2004-2017) for patients with favorable prognostic factors considered for surgery. Immediate surgery was performed within 3 months following the start of induction chemotherapy, while delayed surgery was defined as surgery performed later than 3 months. We compared both groups to those who did not have an operation despite being surgical candidates, as well as to those who were treated with surgery only. Overall mortality was assessed using Cox proportional hazard models adjusting for covariates. Results: A total of 4,294 patients were included, with the majority of patients undergoing induction chemotherapy followed by no surgery (3,370, 78%). The proportion of patients undergoing both immediate and delayed surgery increased over the last decade, but delayed surgery continued to be more common. There were no significant differences in baseline characteristics between the immediate and delayed surgery groups. Higher comorbidity scores were significantly associated with an increased risk of death on multivariable analysis, but the timing of surgery was not. This held true with a sensitivity analysis using 6 months as the definition of delayed surgery. Conclusions: This study shows that delaying surgery following induction chemotherapy does not compromise overall survival in patients with mesothelioma.","PeriodicalId":15167,"journal":{"name":"Journal of Cancer Metastasis and Treatment","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135436722","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The role of adiponectin in gastric cancer 脂联素在癌症中的作用

Journal of Cancer Metastasis and Treatment Pub Date : 2023-09-08 DOI: 10.20517/2394-4722.2023.23

Cheng Ming, Hajime Orita, Shangcheng Yan, Quan Yuan, C. Fedor, Yongyou Wu, Tetsu Fukunaga

{"title":"The role of adiponectin in gastric cancer","authors":"Cheng Ming, Hajime Orita, Shangcheng Yan, Quan Yuan, C. Fedor, Yongyou Wu, Tetsu Fukunaga","doi":"10.20517/2394-4722.2023.23","DOIUrl":"https://doi.org/10.20517/2394-4722.2023.23","url":null,"abstract":"Adiponectin, an adipokine synthesized by adipose tissue, has garnered significant attention in biomedical investigations. Research on its implications suggests that reduced adiponectin levels in the bloodstream might serve as a potential predisposing factor for several types of cancers, including gastric cancer. Although many studies on adiponectin levels in gastric cancer patients have been reported, its predictive role as a biomarker remains controversial. Moreover, the significance of adiponectin receptor expression as a prognostic factor in gastric cancer tissues varies across different research studies, and the precise mechanism by which adiponectin influences the initiation and advancement of gastric cancer remains to be fully elucidated. Furthermore, the anti-inflammatory and postoperative anti-infective effects of adiponectin are worth further investigation. Based on existing studies, it is commonly suggested that in the presence of low adiponectin levels, the stomach might be vulnerable to stimulation or damage from certain carcinogens, promoting gastric cancer development and progression. Considering its complex systemic effects and high serum concentration, adiponectin might serve as a homeostasis regulator and not necessarily as an anti-cancer factor. In this review, we explore the current research available on adiponectin in relation to gastric cancer and discuss its role and corresponding receptors involved in gastric cancer.","PeriodicalId":15167,"journal":{"name":"Journal of Cancer Metastasis and Treatment","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48216927","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0